

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

VOLUNTARY ANNOUNCEMENT

FIRESORB® BIORESORBABLE CORONARY SCAFFOLD SYSTEM OBTAINED APPROVAL FOR MARKETING FROM THE NMPA

This announcement is made by MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business progress and product development of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that on 30 July 2024, the world’s first new generation Firesorb® Bioresorbable Scaffold System (“**Firesorb® Stent**”), self-developed by the Group, obtained the approval for marketing from the National Medical Products Administration of China (the “**NMPA**”), which will further improve the Group’s integrated, precise and intelligent holistic solutions for the diagnosis and treatment of coronary artery-related diseases, in order to serve the comprehensive needs of patients worldwide.

About Firesorb® Stent

- **First Target Eluting Bioresorbable Scaffold System with Reduced Strut Thickness to Same Level as Metal Stents While Maintaining Equal Support**

The Group adopted thin strut design which made Firesorb® Stent the first target eluting bioresorbable scaffold system with reduced strut thickness to same level as metal stents while maintaining equal support.

- **The Rate of Thrombosis of All Patients in the FUTURE-I, II and III Three Trials was only 0.32% at 2-year Follow up, with a Four-year Thrombotic Event of 0% in the RCT Study**

Data from large preclinical studies have shown that Firesorb® Stent is non-inferior to permanent drug-eluting stents in terms of major clinical parameters from publicly available clinical data. Firesorb® Stent has a target lesion failure (TLF) rate of only 4.3% at 4-year follow-up of RCT study. The rate of thrombosis of all patients in the FUTURE-I, II, and III Trials was only 0.32% at 2-year follow up, with four-year thrombotic event of 0% in the RCT study. The imaging results supports that Firesorb® Stent is not inferior to other marketed permanent stents in terms of endothelial coverage rate and speed, and the numerical results of the clinical trial are superior compared to other biodegradable stents.

- **“Target Eluting” Technology to Reduce Effective Drug Load while Achieving Same Efficacy**

Adopting the unique “**target eluting**” technology of MicroPort®, Firesorb® Stent achieves precisely targeted drug application, coating only one side of the stent facing the vessel wall and reducing the effective drug load to one-third of the universal drug load while achieving the same efficacy.

- **Wider Lesion Size Coverage**

As a bioresorbable stent with wider lesion size coverage and applicable to the treatment of small-vessel lesions up to 2.5 millimeters in diameter, Firesorb® Stent solves the problem of accessibility of bioresorbable stent in small-vessel lesion areas.

Meanwhile, the guidewire for rotational atherectomy, which is used in conjunction with the Group’s first self-developed rotational atherectomy catheter system and coronary rotational atherectomy system, has recently obtained marketing approval from the NMPA, and the coronary rotational atherectomy system has entered the NMPA special review approval process for innovative medical devices (the “**Green Path**”).

Impact on the Company

- **Improve the Diagnosis Holistic Medical Solutions for the Treatment of Cardiovascular Diseases to Bring New Growth Momentum**

The marketing approval of Firesorb® Stent and guidewire for rotational atherectomy by the NMPA will further improve the Group's integrated, precise and intelligent holistic solutions for the diagnosis and treatment of coronary artery-related diseases, in order to serve the comprehensive needs of patients worldwide. Leveraging on the commercialisation capability of the Group's existing cardiovascular interventional product channels and overseas platforms, it is believed that new growth momentum will be brought to the Group.

- **Strengthen the Leading Position in the Global Coronary Stent Field**

The incidence of coronary heart disease is trending younger. Bioresorbable stents, which can support diseased blood vessels in the short term and degrade completely in the body in the long term, are at the scientific and technological hub amid the global competition. The approval of Firesorb® Stent will further strengthen the Group's leading position in the global coronary stent field.

- **Application of Technologies Derived from Platform**

The technologies derived from Firesorb® Stent platform are expected to be applied in other areas such as cerebral infarction, peripheral vascular stenosis, and bone trauma in the future, allowing more patients to access internationally leading treatment solutions.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 30 July 2024

As at the date of this announcement, the executive director of the Company is Dr. Zhaohua Chang; the non-executive directors of the Company are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Ms. Weiqin Sun; and the independent non-executive directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* For identification purpose only